Table 1 Description of samples used for the immunofluorescence analysis
From: A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer
Sample No. | Primary tumor/ LN metastasis1 | Tissue origin | Histological result2 |
|---|---|---|---|
1 | tumour | parotid gland | PA |
2 | metastasis | lymph node | SCC |
3 | tumour | hypopharynx | SCC |
4 | tumour | hypopharynx | SCC |
5 | tumour | uvula | SCC |
6 | tumour | skin (left auricle) | BCC |
7 | metastasis | lymph node | SCC |
8 | tumour | hypopharynx | SCC |
9 | metastasis (from 8) | lymph node | SCC |
10 | metastasis | lymph node | SCC |
11 | tumour | skin (nose) | SCC |
12 | tumour | hypopharynx | SCC |
13 | tumour | oral cavity (tongue) | SCC |
14 | metastasis (from 13) | lymph node | SCC |
15 | metastasis (from 8) | lymph node | SCC |
16 | tumour | parotid gland | PA |
17 | tumour | oropharynx | SCC |
18 | tumour | oropharynx | SCC |
19 | tumour | parotid gland | PA |
20 | tumour | parotid gland | PA |
21 | tumour | hypopharynx | SCC |
22 | tumour | larynx (vocal cord) | SCC |
23 | tumour | larynx | SCC |
24 | tumour | larynx | SCC |
25 | metastasis | lymph node | CS |
26 | tumour | oropharynx (tonsil) | SCC |
27 | tumour | larynx | SCC |
28 | tumour | oropharynx | SCC |
29 | tumour | supraglottis | SCC |
30 | tumour | supraglottis | SCC |
31 | tumour | supraglottis | SCC3 |
32 | tumour | oral cavity (lower jaw - alveolar crest) | SCC |
33 | tumour | larynx (glottis - posterior commissure) | SCC |
34 | tumour | oral cavity (palatal arch) | SCC |
35 | tumour | nasopharynx | SCC |
36 | metastasis | lymph node | PDTC |
37 | metastasis | lymph node | SCC |
38 | tumour | oropharynx (vallecula epiglottica) | SCC |
39 | tumour | larynx (epiglottis) | SCC |
40 | tumour | larynx (epiglottis) | SCC |